Consistent with these observations, it has been reported that reduced Top1 expression and/or Top1 catalytic activity in cancer cells is associated with increased resistance to CPTs [45,46], while increased Top1 expression in cancer cells sensitizes CPTs [47,48,49]. This evidence concerns the gene TOP1 and cancer.